CAR-T (Shanghai) Biotechnology Co.,Ltd. Report issue

Government Phase 1 Phase 2

Organization Overview

First Clinical Trial
2018
NCT03658655
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

CAR-T (Shanghai) Biotechnology Co., Ltd. | CAR-T (Shanghai) Biotechnology Co.,Ltd. | CAR-T (Shanghai) Cell Biotechnology Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 1 (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Pneumonia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 5